Trial Profile

Single-center, Open-label, Phase 1 Study Consisting of a Single-dose Pilot Phase and a Randomized, Two-way Crossover, Single-dose Main Phase to Investigate the Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Male Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selexipag (Primary) ; Selexipag (Primary)
Indications Arteriosclerosis obliterans; Pulmonary arterial hypertension; Pulmonary hypertension; Raynaud's disease
Focus Pharmacokinetics
Sponsors Actelion Pharmaceuticals

24 Nov 2016 Results assessing bioavailability of oral (tablet) versus intravenous (i.v.) formulation of selexipag in healthy subjects published in the European Journal of Clinical Pharmacology.
12 Sep 2016 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com